NICE discrimination

Journal of Medical Ethics

Volumn 31, Issue 12, 2005, Pages 683-684

  Rawlins, Michael ^a   Dillon, A ^a  

^a NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COST EFFECTIVENESS ANALYSIS; EDITORIAL; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HUMAN; MEDICAL DECISION MAKING; MEDICAL ETHICS; MEDICAL PROFESSION; NATIONAL HEALTH SERVICE; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; PROFESSIONAL STANDARD; QUALITY ADJUSTED LIFE YEAR; RESOURCE ALLOCATION;

HEALTH CARE AND PUBLIC HEALTH; NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE (GREAT BRITAIN);

ACADEMIES AND INSTITUTES; AGE FACTORS; COST-BENEFIT ANALYSIS; ETHICAL THEORY; HUMANS; LIFE EXPECTANCY; QUALITY OF LIFE; QUALITY-ADJUSTED LIFE YEARS; RESOURCE ALLOCATION; STATE MEDICINE;

EID: 29544439152     PISSN: 03066800     EISSN: None     Source Type: Journal    
DOI: 10.1136/jme.2005.013813     Document Type: Editorial

References (13)

1. Harris J. It's not NICE to discriminate. J Med Ethics 2005;31:373-5.
2. Beauchamp TL, Childress JF. Principles of biomedical ethics. Oxford and New York: Oxford University Press, 2001.
3. National Health Service Act 1977. London: HMSO, 1977.
4. Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA 1991;265:2218-25.
5. Daniels N, Sabin JE. Setting limits fairly: can we learn to share medical resources?. Oxford and New York: Oxford University Press, 2002.
6. Kukathas C, Pettit P. Rawls: a theory of justice and its critics. Stanford: Stanford University Press, 1990.
7. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgements. BMJ 2004;329:224-6.
8. National Institute for Clinical Excellence. Bisphosphonates (alendronate, etidronate, risedronate), selective oestrogen receptor modulators (raloxifene) and parathyroid hormone (teriparatide) for the secondary prevention of osteoporotic fragility fractures in postmenopausal women. Technology appraisal guidance no 87, 2005. http://www.nice.org.uk/page.aspx?o=241349 (accessed 21 Sept 2005).
9. National Institute for Clinical Excellence. Guidance on the use of oseltamivir and amantadine for the prophylaxis of influenza. Technology appraisal guidance no 67, 2003. http://www.nice.org.uk/pdf/67_Flu_prophylaxis_guidance.pdf (accessed 21 Sept 2005).
10. National Institute for Clinical Excellence. Guidance on the use of zanamivir, oseltamivir and amantadine for the treatment of influenza. Technology appraisal guidance no 58, 2005. http://www.nice.org.uk/pdf/58_Flu_fullguidance.pdf (accessed 21 Sept 2005).
11. National Institute for Clinical Excellence. Guidance on the use of cyclo-oxgenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarhritis and rheumatoid arthritis. Technology appraisal guidance no 27, 2001. http://www.nice.org.uk/page.aspx?o=241349 (accessed 21 Sept 2005).
12. Sassi F, Archard L, Le Grand J. Equity and the economic evaluation of health care. Health Technol Assess 2001;5:1-138.
13. National Institute for Clinical Excellence. Assessment and treatment for people with fertility problems. Clinical guideline no 11, 2004, http://www.nice.org.uk/pdf/CG011fullguideline.pdf (accessed 21 Sept 2005).